Up-regulation of SOCS4 Promotes Cell Proliferation and Migration in Esophageal Squamous Cell Carcinoma

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35116557

Authors

Jie Ying

Huan-Huan Huang

Miao-Miao Zhang

Jin-Fei Chen

Affiliations

Soon will be listed here.

Abstract

Background: Suppressors of cytokine signaling family member 4 (SOCS4) was shown to serve critical and multifaceted roles in the progression of numerous cancers, including hepatocellular carcinoma, thyroid cancer, breast cancer, and lung adenocarcinoma. While, the expression and the roles of SOCS4 in esophageal squamous cell carcinoma (ESCC) remain elusive. The current study is aimed to investigate the expression pattern and functions of SOCS4 in ESCC.

Methods: The relationship between SOCS4 and the clinicopathological features of ESCC was analyzed. SOCS4 expression in ESCC tissues was measured by western blot, quantitative real-time polymerase chain reaction (qRT-PCR), and immunohistochemical (IHC) staining. The roles of SOCS4 in modulating ESCC cell behaviors were examined using a series of assays, including cell proliferation assay, cell counting kit-8 (CCK-8) assay, cell cycle analysis, and wound-healing assay.

Results: In human ESCC tissues, SOCS4 expression was up-regulated and correlated with tumor size and lymph node metastasis, however was not correlated with the overall survival (OS) of patients. SOCS4 silencing in ESCC cells resulted in the suppression of cell growth, which was related to the cell cycle. SOCS4 knockdown also inhibited nuclear factor-kappa B (NF-κB) signaling and decreased the migratory potential of ESCC cells.

Conclusions: These findings revealed that increased expression of SOCS4 in ESCC may promote the progression, proliferation, and migration by NF-κB signaling. Inhibition of SOCS4 may be a promising therapeutic strategy for ESCC.

Citing Articles

The Neglected Suppressor of Cytokine Signalling (SOCS): SOCS4-7.

Herrera-Uribe J, Convery O, ALmohammadi D, Weinberg F, Stevenson N Inflammation. 2024; .

PMID: 39460806 DOI: 10.1007/s10753-024-02163-7.

Expression Characteristics, Immune Signature, and Prognostic Value of the SOCS Family Identified by Multiomics Integrative Analysis in Liver Cancer.

Dong Z, Dai B, Wu R, Fang K, Sui C, Geng L Cancer Rep (Hoboken). 2024; 7(9):e2161.

PMID: 39307915 PMC: 11416904. DOI: 10.1002/cnr2.2161.

SPP1 promotes tumor progression in esophageal carcinoma by activating focal adhesion pathway.

Sun J, Tang M, Cai Z J Gastrointest Oncol. 2024; 15(3):818-828.

PMID: 38989403 PMC: 11231845. DOI: 10.21037/jgo-24-302.

Bufalin suppresses esophageal squamous cell carcinoma progression by activating the PIAS3/STAT3 signaling pathway.

Ju Q, Shi Q, Liu C, Fu G, Shi H J Thorac Dis. 2023; 15(4):2141-2160.

PMID: 37197494 PMC: 10183519. DOI: 10.21037/jtd-23-486.

References

Li Z, Metze D, Nashan D, Muller-Tidow C, Serve H, Poremba C . Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol. 2004; 123(4):737-45. DOI: 10.1111/j.0022-202X.2004.23408.x. View

Meng P, Wei J, Geng Y, Chen S, Terpstra M, Huang Q . Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients. BMC Cancer. 2019; 19(1):818. PMC: 6701116. DOI: 10.1186/s12885-019-6025-2. View

Ma J, Mannoor K, Gao L, Tan A, Guarnera M, Zhan M . Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing. Mol Oncol. 2014; 8(7):1208-19. PMC: 4198444. DOI: 10.1016/j.molonc.2014.03.019. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Li R, Ke S, Meng F, Lu J, Zou X, He Z . CiRS-7 promotes growth and metastasis of esophageal squamous cell carcinoma via regulation of miR-7/HOXB13. Cell Death Dis. 2018; 9(8):838. PMC: 6079012. DOI: 10.1038/s41419-018-0852-y. View

Wei L, Huang Y, Zhao R, Zhang J, Liu Q, Liang W . Detection of promoter methylation status of suppressor of cytokine signaling 3 (SOCS3) in tissue and plasma from Chinese patients with different hepatic diseases. Clin Exp Med. 2017; 18(1):79-87. DOI: 10.1007/s10238-017-0473-2. View

Palmer D, Restifo N . Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol. 2009; 30(12):592-602. PMC: 2787651. DOI: 10.1016/j.it.2009.09.009. View

Meng X, Dong X, Wang W, Yang L, Zhang X, Li Y . Natural Borneol Enhances Paclitaxel-Induced Apoptosis of ESCC Cells by Inactivation of the PI3K/AKT. J Food Sci. 2018; 83(5):1436-1443. DOI: 10.1111/1750-3841.14143. View

Choi J, Song N, Han S, Chung S, Sung H, Lee J . The associations between immunity-related genes and breast cancer prognosis in Korean women. PLoS One. 2014; 9(7):e103593. PMC: 4116221. DOI: 10.1371/journal.pone.0103593. View

10.

Xiao X, Yang D, Gong X, Mo D, Pan S, Xu J . miR-1290 promotes lung adenocarcinoma cell proliferation and invasion by targeting SOCS4. Oncotarget. 2018; 9(15):11977-11988. PMC: 5844722. DOI: 10.18632/oncotarget.24046. View

11.

Song M, Yoon G, Choi J, Kim E, Liu X, Oh H . Janus kinase 2 inhibition by Licochalcone B suppresses esophageal squamous cell carcinoma growth. Phytother Res. 2020; 34(8):2032-2043. DOI: 10.1002/ptr.6661. View

12.

Mei Z, Chen S, Chen C, Xiao B, Li F, Wang Y . Interleukin-23 Facilitates Thyroid Cancer Cell Migration and Invasion by Inhibiting SOCS4 Expression via MicroRNA-25. PLoS One. 2015; 10(10):e0139456. PMC: 4593557. DOI: 10.1371/journal.pone.0139456. View

13.

Li F, Zhang Z, Wang P, Wen P, Xu Q, Wang Y . ALC1 knockdown enhances cisplatin cytotoxicity of esophageal squamous cell carcinoma cells by inhibition of glycolysis through PI3K/Akt pathway. Life Sci. 2019; 232:116679. DOI: 10.1016/j.lfs.2019.116679. View

14.

Starska K, Forma E, Lewy-Trenda I, Stasikowska O, Brys M, Krajewska W . The expression of SOCS1 and TLR4-NFkappaB pathway molecules in neoplastic cells as potential biomarker for the aggressive tumor phenotype in laryngeal carcinoma. Folia Histochem Cytobiol. 2010; 47(3):401-10. DOI: 10.2478/v10042-009-0075-2. View

15.

Nakagawa T, Iida S, Osanai T, Uetake H, Aruga T, Toriya Y . Decreased expression of SOCS-3 mRNA in breast cancer with lymph node metastasis. Oncol Rep. 2007; 19(1):33-9. View

16.

Inagaki-Ohara K, Kondo T, Ito M, Yoshimura A . SOCS, inflammation, and cancer. JAKSTAT. 2013; 2(3):e24053. PMC: 3772102. DOI: 10.4161/jkst.24053. View

17.

Guo W, Li W, Yuan L, Mei X, Hu W . MicroRNA-106a-3p Induces Apatinib Resistance and Activates Janus-Activated Kinase 2 (JAK2)/Signal Transducer and Activator of Transcription 3 (STAT3) by Targeting the SOCS System in Gastric Cancer. Med Sci Monit. 2019; 25:10122-10128. PMC: 6948289. DOI: 10.12659/MSM.919610. View

18.

Gonzalez-Plaza J, Hulak N, Garcia-Fuentes E, Garrido-Sanchez L, Zhumadilov Z, Akilzhanova A . Oesophageal squamous cell carcinoma (ESCC): Advances through omics technologies, towards ESCC salivaomics. Drug Discov Ther. 2015; 9(4):247-57. DOI: 10.5582/ddt.2015.01042. View

19.

Ha Y, Dai Y, Wufuer D, Pidayi M, Anasihan G, Chen L . Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling. Neoplasma. 2019; 67(1):54-60. DOI: 10.4149/neo_2019_190131N94. View

20.

Chen Y, Wang D, Peng H, Chen X, Han X, Yu J . Epigenetically upregulated oncoprotein PLCE1 drives esophageal carcinoma angiogenesis and proliferation via activating the PI-PLCε-NF-κB signaling pathway and VEGF-C/ Bcl-2 expression. Mol Cancer. 2019; 18(1):1. PMC: 6320601. DOI: 10.1186/s12943-018-0930-x. View